Merck & Co., Inc. (NYSE:MRK) Stock Holdings Raised by Butensky & Cohen Financial Security Inc.

Butensky & Cohen Financial Security Inc. lifted its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 24.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,716 shares of the company’s stock after buying an additional 8,613 shares during the quarter. Merck & Co., Inc. makes up about 1.6% of Butensky & Cohen Financial Security Inc.’s portfolio, making the stock its 10th biggest position. Butensky & Cohen Financial Security Inc.’s holdings in Merck & Co., Inc. were worth $3,986,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Merck & Co., Inc. in the first quarter worth approximately $25,000. Landmark Wealth Management LLC purchased a new position in Merck & Co., Inc. during the 1st quarter worth $25,000. Front Row Advisors LLC increased its holdings in Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares during the period. Okabena Investment Services Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter worth $27,000. Finally, Western Pacific Wealth Management LP purchased a new position in Merck & Co., Inc. during the 4th quarter worth $29,000. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $87.51 on Friday. The stock has a 50-day moving average of $88.83 and a two-hundred day moving average of $87.81. Merck & Co., Inc. has a one year low of $71.50 and a one year high of $95.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39. The stock has a market cap of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company had revenue of $14.59 billion during the quarter, compared to analysts’ expectations of $13.85 billion. During the same quarter in the previous year, the firm posted $1.31 EPS. The firm’s revenue was up 28.0% compared to the same quarter last year. As a group, research analysts predict that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Analyst Ratings Changes

MRK has been the topic of several research reports. UBS Group raised their price objective on Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a report on Monday, July 18th. Daiwa Capital Markets upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $89.00 to $102.00 in a report on Wednesday, July 6th. Berenberg Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $100.00 in a report on Wednesday, September 14th. Atlantic Securities lifted their price target on Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Finally, Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, June 24th. They issued a “buy” rating and a $100.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.